Traferox Technologies, Inc. appears in FDA device records as the applicant for two distinct organ-support product lines. The TorEx Lung Perfusion System, filed under PMA P250025, received approval on July 15, 2026, with a stated indication for continuous normothermic machine perfusion of donor lungs initially deemed unsuitable for transplantation, allowing ex vivo reassessment in adults for up to six hours. The X°Port Heart Preservation System, filed as K261913, received a substantially equivalent determination on September 16, 2026. Both filings list the same Mississauga, Ontario address, which is a filing address rather than a verified headquarters. [4][3][7]
TorEx Lung Perfusion System and its filing history
The P250025 approval order describes the TorEx Lung Perfusion System as including a mobile cart with embedded software, a single-use sterile Organ Chamber and Cannulae set, and use with TorEx Lung Perfusate solution to perform ex vivo lung perfusion. The order states that the system is used to evaluate donated lung quality while the final suitability determination remains with the transplanting surgeon. The device carries product code PHO and Class III designation, with the generic name normothermic preservation system for transplantation of initially unacceptable donor lungs. [4][1]
Two post-approval study protocol supplements followed the original approval. P250025/S001 and P250025/S002 were both received on August 7, 2026 and both decided APPR on October 30, 2026, each described as a Normal 180 Day Track No User Fee supplement with the reason Postapproval Study Protocol. The associated approval statement records approval of the PAS protocol submitted to comply with the conditions of the original approval order. [1][2]
X°Port Heart Preservation System clearance
K261913 covers the X°Port Heart Preservation System under product code MSB, regulation number 876.5880, and Class II. The FDA record shows a Traditional clearance type, a decision date of September 16, 2026, a receipt date of June 8, 2026, and a decision description of Substantially Equivalent. The openFDA device name for this product code is system and accessories, isolated heart, transport and preservation. [3]
What the collection counts do and do not show
MedtechLedger links four FDA records in this collection: three PMA entries and one 510(k) entry. The recorded decisions are three APPR entries and one SESE entry. These counts describe the linked filings as of the collection’s retrieval date, rather than the company’s total sales, complete portfolio or safety performance. This four-record sample contains no recall entries. [1][2][3][4]
Company-published material describes the TorEx platform as designed to enable functional assessment of donor lungs outside the body prior to transplantation, and the company announced the PMA on July 16, 2026. A separate company page describes the TorEx Lung Perfusion System as enabling assessment of marginal donor lungs. These characterizations come from the company's own publications, not from FDA efficacy findings. [7][9]
Corporate identity and published context
The company's website states that Traferox Technologies Inc. combines expertise with research pioneered by University Health Network's Toronto General Hospital. The Instructions for Use for the TorEx system lists Traferox Technologies Inc. at 3505 Laird Rd. Unit 16, Mississauga, ON, Canada, matching the address in the FDA filings, and identifies the document as revision 13 dated 2026-09. No parent company, ownership structure, or customer list is verified in the public documents. [10][5]





